Related Experiment Video
Updated: Nov 15, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions
Minru Liao1, Jin Zhang1, Guan Wang1
1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Abstract:
Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, but an effective targeted therapy has not been well-established so far. Considering the lack of effective targets, where do we go next in the current TNBC drug development? A promising intervention for TNBC might lie in de novo small-molecule drugs that precisely target different molecular characteristics of TNBC. However, an ideal single-target drug discovery still faces a huge challenge. Alternatively, other new emerging strategies, such as dual-target drug, drug repurposing, and combination strategies, may provide new insight into the improvement of TNBC therapeutics. In this review, we focus on summarizing the current situation of a series of candidate small-molecule drugs in TNBC therapy, including single-target drugs, dual-target drugs, as well as drug repurposing and combination strategies that will together shed new light on the future directions targeting TNBC vulnerabilities with small-molecule drugs for future therapeutic purposes.
Insights
Developing new small-molecule drugs for triple-negative breast cancer (TNBC) is crucial. Emerging strategies like dual-target drugs and drug repurposing offer promising avenues for effective TNBC therapeutics.
Area of Science:
- Oncology
- Pharmacology
- Drug Discovery
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype lacking established targeted therapies.
- Current TNBC drug development faces challenges due to the absence of effective molecular targets.
- Novel therapeutic strategies are urgently needed to improve treatment outcomes for TNBC patients.
Purpose of the Study:
- To review current small-molecule drug candidates for triple-negative breast cancer (TNBC) therapy.
- To explore emerging strategies including dual-target drugs, drug repurposing, and combination therapies.
- To identify future directions for targeting TNBC vulnerabilities with small-molecule drugs.
Main Methods:
- Literature review of recent advancements in small-molecule drug development for TNBC.
- Analysis of single-target, dual-target, repurposed, and combination drug strategies.
- Synthesis of current research findings to highlight therapeutic potential.
Main Results:
- Single-target drug discovery for TNBC remains challenging.
- Dual-target drugs, drug repurposing, and combination strategies show significant therapeutic promise.
- Various small-molecule candidates are under investigation for TNBC treatment.
Conclusions:
- Emerging strategies offer new hope for effective triple-negative breast cancer (TNBC) treatment.
- Targeting TNBC vulnerabilities with innovative small-molecule drugs is a key future direction.
- Continued research into novel therapeutic approaches is essential for improving patient survival rates.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
